{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:04:28Z","timestamp":1771261468275,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2004,2,1]]},"DOI":"10.1038\/sj.bmt.1704344","type":"journal-article","created":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T08:10:03Z","timestamp":1070266203000},"page":"271-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome"],"prefix":"10.1038","volume":"33","author":[{"given":"P N","family":"Mollee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A D","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D L","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A K","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,12,1]]},"reference":[{"key":"BF1704344_CR1","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.172.3988.1150","volume":"172","author":"GG Glenner","year":"1971","unstructured":"Glenner GG, Terry W, Harada M et al. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 1971; 172: 1150\u20131151.","journal-title":"Science"},{"key":"BF1704344_CR2","first-page":"45","volume":"32","author":"RA Kyle","year":"1995","unstructured":"Kyle RA, Gertz MA . Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45\u201359.","journal-title":"Semin Hematol"},{"key":"BF1704344_CR3","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comenzo RL, Skinner M . The systemic amyloidoses. N Engl J Med 1997; 337: 898\u2013909.","journal-title":"N Engl J Med"},{"key":"BF1704344_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00005792-197507000-00001","volume":"54","author":"RA Kyle","year":"1975","unstructured":"Kyle RA, Bayrd ED . Amyloidosis: review of 236 cases. Medicine (Baltimore) 1975; 54: 271\u2013299.","journal-title":"Medicine (Baltimore)"},{"key":"BF1704344_CR5","first-page":"665","volume":"58","author":"RA Kyle","year":"1983","unstructured":"Kyle RA, Greipp PR . Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665\u2013683.","journal-title":"Mayo Clin Proc"},{"key":"BF1704344_CR6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood.V93.3.1062","volume":"93","author":"RA Kyle","year":"1999","unstructured":"Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999; 93: 1062\u20131066.","journal-title":"Blood"},{"key":"BF1704344_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","volume":"100","author":"M Skinner","year":"1996","unstructured":"Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290\u2013298.","journal-title":"Am J Med"},{"key":"BF1704344_CR8","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"RA Kyle","year":"1997","unstructured":"Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202\u20131207.","journal-title":"N Engl J Med"},{"key":"BF1704344_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.1999.17.1.262","volume":"17","author":"MA Gertz","year":"1999","unstructured":"Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17: 262\u2013267.","journal-title":"J Clin Oncol"},{"key":"BF1704344_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1703200","volume":"28","author":"V Sanchorawala","year":"2001","unstructured":"Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637\u2013642.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704344_CR11","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","volume":"19","author":"A Dispenzieri","year":"2001","unstructured":"Dispenzieri A, Lacy MQ, Kyle RA et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350\u20133356.","journal-title":"J Clin Oncol"},{"key":"BF1704344_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.bmt.1702005","volume":"24","author":"N Saba","year":"1999","unstructured":"Saba N, Sutton D, Ross H et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853\u2013855.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704344_CR13","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","volume":"91","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662\u20133670.","journal-title":"Blood"},{"key":"BF1704344_CR14","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","volume":"88","author":"RL Comenzo","year":"1996","unstructured":"Comenzo RL, Vosburgh E, Simms RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801\u20132806.","journal-title":"Blood"},{"key":"BF1704344_CR15","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V87.7.3063.bloodjournal8773063","volume":"87","author":"P Moreau","year":"1996","unstructured":"Moreau P, Milpied N, de Faucal P et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996; 87: 3063\u20133064.","journal-title":"Blood"},{"key":"BF1704344_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","volume":"101","author":"P Moreau","year":"1998","unstructured":"Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766\u2013769.","journal-title":"Br J Haematol"},{"key":"BF1704344_CR17","first-page":"324a","volume":"92","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Falk R, Sanchorawala V et al. Treating AL amlyoidosis (AL) with dose-intensive melphalan: outcomes in 102 patients. Blood 1998; 92: 324a.","journal-title":"Blood"},{"key":"BF1704344_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.bmt.1702178","volume":"25","author":"MA Gertz","year":"2000","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A . Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000; 25: 465\u2013470.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704344_CR19","doi-asserted-by":"publisher","first-page":"860a","DOI":"10.1182\/blood.V98.3.860","volume":"98","author":"V Sanchorawala","year":"2001","unstructured":"Sanchorawala V, Taper J, Seldin DC et al. High dose intravenous melphalan and autologous stem cell transplantation for the treatment of AL amyloidosis: morbidity and mortality. Blood 2001; 98: 860a.","journal-title":"Blood"},{"key":"BF1704344_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1046\/j.1523-1755.2003.00813.x","volume":"63","author":"LF Casserly","year":"2003","unstructured":"Casserly LF, Fadia A, Sanchorawala V et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003; 63: 1051\u20131057.","journal-title":"Kidney Int"},{"key":"BF1704344_CR21","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","volume":"99","author":"RL Comenzo","year":"2002","unstructured":"Comenzo RL, Gertz MA . Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276\u20134282.","journal-title":"Blood"},{"key":"BF1704344_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJM200004133421508","volume":"342","author":"ME Lippman","year":"2000","unstructured":"Lippman ME . High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1119\u20131120.","journal-title":"N Engl J Med"},{"key":"BF1704344_CR23","first-page":"815a","volume":"98","author":"V Sanchorawala","year":"2001","unstructured":"Sanchorawala V, Wright DG, Seldin DC et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Blood 2001; 98: 815a.","journal-title":"Blood"},{"key":"BF1704344_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1046\/j.1365-2141.1999.01216.x","volume":"104","author":"RL Comenzo","year":"1999","unstructured":"Comenzo RL, Sanchorawala V, Fisher C et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999; 104: 553\u2013559.","journal-title":"Br J Haematol"},{"key":"BF1704344_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bmt.1702643","volume":"26","author":"MA Gertz","year":"2000","unstructured":"Gertz MA, Lacy MQ, Gastineau DA et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000; 26: 963\u2013969.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704344_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s002590050272","volume":"25","author":"PN Hawkins","year":"1998","unstructured":"Hawkins PN, Aprile C, Capri G et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med 1998; 25: 701\u2013708.","journal-title":"Eur J Nucl Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704344","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:50:24Z","timestamp":1648079424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,2,1]]}},"alternative-id":["BF1704344"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704344","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,1]]},"assertion":[{"value":"10 February 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}